Objective outcome measures: Collecting meaningful data on alopecia areata

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:79

Article

Olsen, Elise A.¹  Roberts, Janet²  Sperling, Leonard³  Tosti, Antonella⁴  Shapiro, Jerry⁵  McMichael, Amy⁶  Bergfeld, Wilma⁷  Callender, Valerie⁸  Mirmirani, Paradi⁹  Washenik, Ken^5,10  Whiting, David¹¹  Cotsarelis, George¹²  Hordinsky, Maria¹³ 

[1] Duke Univ, Med Ctr, Box 3294, Durham, NC 27710 USA

[2] Northwest Dermatol & Res Ctr, Portland, OR USA

[3] HCT Pathol Serv, Baltimore, MD USA

[4] Univ Miami, Miami, FL USA

[5] NYU, New York, NY USA

[6] Wake Forest Baptist Hlth Med Ctr, Winston Salem, NC USA

[7] Cleveland Clin, Cleveland, OH 44106 USA

[8] Howard Univ, Coll Med, Washington, DC USA

[9] Permanente Med Grp Inc, Vallejo, CA USA

[10] Bosley Med Grp, Beverly Hills, CA USA

[11] Baylor Hair Res Ctr, Dallas, TX USA

[12] Univ Penn, Philadelphia, PA 19104 USA

[13] Univ Minnesota, Minneapolis, MN USA

关键词: ALODEX score;    alopecia areata;    assessment measures;    outcome measures;    response criteria;    SALT score;   

DOI  :  10.1016/j.jaad.2017.10.048

来源: Elsevier

【 摘 要 】

Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration-approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.

【 授权许可】

Free